Milton Weinsteine's Insights on the Development, Use, and Methodologic Problems in Cost-Effectiveness Analysis

Journal of Nursing Scholarship

Volumn 30, Issue 3, 1998, Pages 223-228

  Buerhaus, Peter I ^a,b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b Harvard Nursing Research Institute   (United States)

Author keywords

Cost effectiveness analysis; Health resources allocation

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; ECONOMICS; HUMAN; INTERVIEW; METHODOLOGY; NURSING RESEARCH; UNITED STATES;

COST-BENEFIT ANALYSIS; HUMANS; NURSING RESEARCH; RESEARCH DESIGN; UNITED STATES;

EID: 0031604464     PISSN: 15276546     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Bush, J. (1973). Cost-effectiveness using a health status index: Analysis of the New York state PKU screening program. In R. Berg (Ed.). Health status indexes: Proceedings of a conference. Chicago: Hospital Research and Educational Trust.
2. Drummond, M.F., Stoddart, G.L., & Torrance, G.W. (1987) Methods for the economic evaluation of health care programmes. Oxford, England: Oxford University Press.
3. Eddy, D.M. (1990). Screening for cervical cancer. Annals of Internal Medicine, 113, 214-226.
4. Eisenberg, J.M. (1989). Clinical economics: A guide to economic analysis of clinical practice. JAMA, 262, 2879-2886.
5. Gold, M.R., Siegel, J.E., Russell, L.B., & Weinstein, M.C., Eds. (1996). Cost-effectiveness in health and medicine. New York: Oxford University Press.
6. Goldman, L., Weinstein, M.C., Goldman, P.A., & Williams, L.W. (1991). Cost-effectiveness of HMG-CoA reductase inhibition for primary and secondary prevention of coronary heart disease. JAMA, 265, 1145-1151.
7. Klarman, H., Francis, I.O., & Rosanthall, G.D. (1968) Cost-effectiveness analysis applied to the treatment of chronic renal disease. Medical Care, 6, 48.
8. National Cholesterol Education Program (NCEP). (1994). The second report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Circulation 89: 1329-1445.
9. Office of Technology Assessment (OTA), U.S. Congress. (1979). Review of selected federal vaccine and immunization policies based on case studies of pneumococcal vaccine. Washington, DC: U.S. Government Printing Office.
10. Russell, L.B., Gold, M.R., Siegel, J.E., Daniels, N., & Weinstein, M.C. (1996). The role of cost-effectiveness analysis in health and medicine. JAMA, 276, 1172-1177.
11. Siegel, J.E., Weinstein, M.C., Russell, L.B., & Gold, M.R. (1996). Recommendations for reporting cost-effectiveness analyses. JAMA, 276(16), 1339-1341.
12. Sisk, J.W., Sanders, C.R., Riddiough, M.A., & Bell, J.C. (1980). Cost-effectiveness of vaccination against pneumococcal pneumonia. New England Journal of Medicine, 330, 553-559.
13. Torrance, G.W., Thomas, W.H., & Sacket, D.L. (1972). A utility maximization model for evaluation of health care programs. Health Services Research, 7, 118-133.
14. Weinstein, M.C., Siegel, J.E., Gold, M.R., Kamlet, M.S., & Russell, L.B. (1996). Recommendations of the panel on cost-effectiveness in health and medicine. JAMA, 276, 1253-1258.
15. Weinstein, M.C., & Stason, W.B. (1977). Foundations of cost-effectiveness analysis for health and medical practices. New England Journal of Medicine 296, 716-721.